Ventricle Health

📉 Early SGLT2i Use = Greater Value in HFpEF/HFmrEF A new Journal of Cardiac Failure cost-effectiveness analysis finds that the sooner dapagliflozin is initiated, the greater the economic and clinical return—especially after a recent heart failure hospitalization (HHF). 📊 Key findings (DELIVER trial modeling, n=6,263): • 💰 ICER dropped to £3,493/QALY when SGLT2i was started within 1 month of HHF • Starting ≤6 months post-HF diagnosis yielded ICER of £6,033/QALY • In contrast, starting >5 years post-diagnosis: £9,108/QALY • All ICERs were well below UK WTP threshold (£20,000/QALY), but value was highest with earlier initiation 🔍 Mechanisms of cost-effectiveness shift: • Early post-HHF initiation → more event reduction = greater cost offsets • Early post-diagnosis initiation → more HRQoL improvement = greater QALY gains 🧩 Comment This study reinforces that delaying initiation of SGLT2 inhibitors leaves both clinical and economic value on the table. Patients recently hospitalized or newly diagnosed represent high-yield, high-risk windows—and yet, inertia remains common. 📣 Take-home: In HFpEF/HFmrEF, SGLT2i timing matters—not just for outcomes, but for health system value. Early means smarter. The views and opinions expressed in my posts are solely my own, made in my capacity as a private individual, medical doctor, and researcher. They do not represent or reflect the views, policies, or positions of my employer, colleagues, or any affiliated organizations. My posts are intended for informational and discussion purposes only. https://lnkd.in/eUwH2aXN

Heart failure often goes undiagnosed until it’s too late. But that can change. A new study published in the JACC: Advances highlights the critical need for proactive screening and early detection of heart failure in at-risk populations. Key takeaway: In the primary care setting nearly 40% of at-risk patients screened using Vivio® showed evidence of previously unrecognized heart failure. At Ventric Health, we believe that early detection of heart failure is the key to changing outcomes—especially for those most at risk. Read the full article here: https://lnkd.in/ehUgbubD #HeartFailure #EarlyDetection #HealthEquity 

🧪 CONFIDENCE Trial: Doubling Down on CKD in T2D NEJM | June 2025 | Finerenone + Empagliflozin Can combining finerenone and empagliflozin offer additive kidney protection in patients with CKD and type 2 diabetes (T2D)? The CONFIDENCE trial—an international, double-blind, randomized trial—sought to answer this question in 800 patients already on RAS blockade. 🔬 Study Snapshot • Population: Adults with T2D, albuminuria (UACR 100–5000 mg/g), and eGFR 30–90 mL/min/1.73 m² • Arms:  1. Finerenone  2. Empagliflozin  3. Combination • Primary endpoint: % change in log-transformed UACR at 180 days 📉 Primary Outcome at Day 180 • UACR ↓ 52% with combination • ↓ 32% with finerenone alone • ↓ 29% with empagliflozin alone → Combination therapy achieved a 29–32% greater reduction in UACR vs either monotherapy (P<0.001) 📊 Proportion Achieving Albuminuria Reduction at Day 180 • >30% UACR reduction: 70% (combo) vs 52% (finerenone) vs 52% (empagliflozin) • >50% UACR reduction: 55% (combo) vs 36% (finerenone) vs 32% (empagliflozin) 🩺 Safety Profile • eGFR decline >30% at Day 30: 6.3% (combo) vs 3.8% (finerenone) vs 1.1% (empagliflozin) • Hyperkalemia (K⁺ >5.5 mmol/L): 15.3% (combo) vs 18.6% (finerenone) vs 9.7% (empagliflozin) • Serious adverse events: <8% in all arms • Discontinuation due to adverse events: <5% 📌 Key Insights ✅ Combination therapy produced rapid and greater albuminuria reduction ✅ UACR improved within 2 weeks; >40% reduction by Day 90 ✅ Albuminuria rebounded after drug withdrawal, suggesting sustained dosing may be required ✅ No excess in serious safety signals or mortality with combination use ✅ Results support upfront dual strategy over sequential step-up therapy 💭 Comment When two mechanisms converge—finerenone’s anti-fibrotic and SGLT2i’s hemodynamic & metabolic effects—we may finally be moving from partial protection to a more complete renal defense in diabetic kidney disease. Should early dual therapy become the new standard? — The views and opinions expressed in my posts are solely my own, made in my capacity as a private individual, medical doctor, and researcher. They do not represent or reflect the views, policies, or positions of my employer, colleagues, or any affiliated organizations. My posts are intended for informational and discussion purposes only. https://lnkd.in/em-RXysi

Spread the word! We're hiring a telehealth nurse to help patients be successful on their heart failure journey. Please visit our website VentricleHealth.com to apply and contact Nicole Russo, MS PHR for any other inquiries. #Hiring #TelehealthJobs #NurseJobs https://lnkd.in/eQiXfFwh

The ACC’s 🆕 “HF in a Box” toolkit supports clinicians in managing #HeartFailure, offering resources to integrate #SGLT2 inhibitors into therapy alongside established treatment options. Explore lectures, guides, infographics and more: https://bit.ly/3FuROpn